Shanghai Junshi Biosciences Co., Ltd. Announcement on the Results of Shareholding Increase by the Controlling Shareholder and One of the Actual Controllers and Chairman, and the Equity Change Reaching the 1% Threshold

Log in to the Sina Finance app and search for 【disclosure of information】 to view evaluation grade details

Stock code: 688180 Stock abbreviation: Junshi Biosciences Announcement No.: Lin 2026-022

Shanghai Junshi Biosciences Pharmaceutical Technology Co., Ltd.

Announcement on the Results of the Increase in Shareholdings by One of the Controlling Shareholder, the Actual Controller, and Also Chairman of the Board of Directors, and the Change in Equity That Reached the 1% Threshold

The board of directors of the Company, all directors, and relevant shareholders warrant that this announcement contains no false records, misleading statements, or material omissions, and assume legal responsibility under law for the authenticity, accuracy, and completeness of the contents of this announcement.

Key Matters to Note:

● Information on the previously disclosed shareholding increase plan

Shanghai Junshi Biosciences Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “Company”) has been planned by the Company’s controlling shareholder, one of the actual controllers, and also the chairman of the board of directors, Mr. Xiong Jun, to increase the Company’s A-share and H-share holdings within 12 months starting from April 12, 2025, by using methods permitted by the trading systems of the Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited (including, but not limited to, centralized bidding and block trades, etc.), with a total amount of not less than RMB 100 million, including an amount for A-share increases of not less than RMB 50 million (hereinafter referred to as the “Current Shareholding Increase Plan”).

● Implementation results of the shareholding increase plan

On March 31, 2026, the Company received from Mr. Xiong Jun a notice letter titled “Notice Regarding the Completion of the Implementation of the Shareholding Increase Plan of Shanghai Junshi Biosciences Pharmaceutical Technology Co., Ltd.” From April 12, 2025 to March 31, 2026, Mr. Xiong Jun increased the Company’s A-share and H-share holdings in total by 3,259,495 shares, accounting for 0.32% of the Company’s total share capital. The cumulative transaction amount was RMB 100,638,052.19, which has exceeded the lower limit of the intended increase amount under the Current Shareholding Increase Plan. The Current Shareholding Increase Plan has been fully implemented.

● Details of the change in equity

After the current change in equity, the controlling shareholder, the actual controller, Mr. Xiong Jun, Mr. Xiong Fengxiang, and their concerted action parties, namely Shanghai Baoying Asset Management Co., Ltd., Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management Co., Ltd., Zhou Qing, Liu Xiaoling, and Wang Lifang, in aggregate hold the Company. The aggregate shareholding percentage increased from 17.92% to 18.24%, and the change in equity reached the integer multiples of the 1% threshold.

■

I. Basic information on the parties increasing shareholdings

■

Note 1: Before implementation of the shareholding increase plan, Mr. Xiong Jun directly held 87,856,618 shares of the Company (including 87,854,018 A shares and 2,600 H shares; among which H shares were held on his behalf by HKSCC NOMINEES LIMITED as the nominee holder).

Note 2: The shareholding percentage before the implementation of the shareholding increase plan is calculated based on the Company’s current total share capital of 1,026,689,871 shares.

The above parties increasing shareholdings have concerted action parties:

■

Note: The shareholding percentage is calculated based on the Company’s total share capital of 1,026,689,871 shares.

II. Implementation results of the shareholding increase plan

(1) Implementation results of the shareholding increase plan

■

(2) Whether the actual number of shares increased reaches the lower limit of the shareholding increase plan √ Yes □ No

During the implementation period of the shareholding increase, Mr. Xiong Jun increased the Company’s A-share and H-share holdings in total by 3,259,495 shares, accounting for 0.32% of the Company’s total share capital. The cumulative amount increased was RMB 100,638,052.19, which exceeded the lower limit of the amount intended to be increased under the Current Shareholding Increase Plan. The Current Shareholding Increase Plan has been completed.

III. Basic information on the change in equity reaching the 1% threshold

Due to the completion of the Current Shareholding Increase Plan, the controlling shareholder and actual controller, Mr. Xiong Jun, Mr. Xiong Fengxiang, and their concerted action parties, namely Shanghai Baoying Asset Management Co., Ltd., Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management Co., Ltd., Zhou Qing, Liu Xiaoling, and Wang Lifang, collectively increased the number of shares held from 183,983,186 shares (including 183,980,586 A shares and 2,600 H shares) to 187,242,681 shares (including 186,345,481 A shares and 897,200 H shares). The proportion of the Company’s total share capital increased from 17.92% to 18.24%. The change in equity reached the 1% threshold. The specific details are as follows:

■

Note 1: The proportion of shares held before and after this change in equity is calculated based on the Company’s total share capital of 1,026,689,871 shares.

Note 2: The rounding differences between the sums of individual items and the totals shown in the above table are due to rounding.

IV. Other explanations

(1) During the implementation process of this shareholding increase plan, the shareholding-increasing parties have complied with the relevant provisions on listed company equity changes and stock trading sensitive periods issued by the China Securities Regulatory Commission, the Shanghai Stock Exchange, and The Stock Exchange of Hong Kong Limited.

(2) The Company has, in accordance with the provisions of relevant laws, administrative regulations, departmental rules, and normative documents, including the Company Law of the People’s Republic of China, the Securities Law of the People’s Republic of China, the Measures for the Administration of Takeover of Listed Companies, the Shanghai Stock Exchange’s Listing Rules for Science and Technology Innovation Board stocks, the Rules for the Listing of Securities of The Stock Exchange of Hong Kong Limited, and others, continued to monitor the progress of the Current Shareholding Increase Plan and has timely fulfilled its information disclosure obligations.

(3) This shareholding increase plan has been fully implemented. It will not lead to the Company’s share distribution failing to meet the listing requirements, nor will it result in any change in the controlling shareholder and the actual controller.

(4) The current change in equity is caused by Mr. Xiong Jun’s fulfillment of the current shareholding increase plan. It does not involve a tender offer, and it also does not involve an information disclosure obligation for the disclosing party to disclose an equity change report.

This announcement is hereby given.

Shanghai Junshi Biosciences Pharmaceutical Technology Co., Ltd.

Board of Directors

April 1, 2026

A wealth of information and precise interpretation—available in the Sina Finance app